CD4 and CD8 T cell responses against XAGE-1b in lung adenocarcinoma patients, leading to the hypothesis that XAGE-1b might be considered a potential antigen for tumor immunotherapy [15]. This evidence concerns the gene XAGE1B and lung adenocarcinoma.